Symbols / NTBLQ $0.00 +0.00% Notable Labs, Ltd.

Healthcare • Biotechnology • United States • PNK
NTBLQ Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Ms. Kaile Zagger
Exch · Country PNK · United States
Market Cap 96.00
Enterprise Value -2.30M
Income -10.54M
Sales 313.00K
FCF (ttm) -11.46M
Book/sh 0.74
Cash/sh 0.42
Employees 16
Insider 10d —
IPO Oct 17, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.00
PEG —
P/S 0.00
P/B 0.00
P/C —
EV/EBITDA 0.15
EV/Sales -7.34
Quick Ratio 1.70
Current Ratio 2.77
Debt/Eq 24.98
LT Debt/Eq —
EPS (ttm) -1.09
EPS next Y -3.56
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2024-08-14
Earnings (prior) 2024-08-14
ROA -106.09%
ROE —
ROIC —
Gross Margin 37.06%
Oper. Margin -2,690.00%
Profit Margin 0.00%
Shs Outstand 9.66M
Shs Float 7.41M
Insider Own 40.16%
Instit Own 2.12%
Short Float 8.05%
Short Ratio 8.21
Short Interest 501.99K
52W High 0.00
vs 52W High -99.00%
52W Low 0.00
vs 52W Low 0.00%
Beta 24.36
Impl. Vol. —
Rel Volume —
Avg Volume 0.00
Volume 14.16K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive medicines for patients with cancer. The company, through its proprietary Predictive Medicines Platform (PMP), bio-simulates a patient's cancer treatment and predicts whether patient will clinically respond to their actual treatment. Its PMP is designed to identify and select patients expected to be clinically responsive prior to the initiation of their treatment and enable fast-track therapeutic development in this patient population. The company's lead product is Volasertib, a polo like kinase 1 inhibitor to induce cell cycle arrest and apoptosis in various cancer cells. It is also developing two candidate predictive medicines and clinical-stage candidates for development in platform-predicted responders with acute myeloid leukemia. The company is based in Foster City, California. On October 13, 2024, Notable Labs, Ltd. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-21.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-09-20 down JMP Securities Market Outperform → Market Perform —
2024-05-16 main Chardan Capital Buy → Buy $5
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.31
+3775.00%
0.01
-97.19%
0.28
Operating Revenue
0.31
+3775.00%
0.01
-97.19%
0.28
Cost Of Revenue
0.20
0.00
—
Reconciled Cost Of Revenue
0.20
0.00
—
Gross Profit
0.11
+1312.50%
0.01
-97.19%
0.28
Operating Expense
14.77
+14.21%
12.93
-24.81%
17.20
Research And Development
4.71
-39.48%
7.78
-32.22%
11.47
Selling General And Administration
10.06
+95.19%
5.16
-9.97%
5.73
General And Administrative Expense
10.06
+95.19%
5.16
-9.97%
5.73
Other Gand A
10.06
+95.19%
5.16
-9.97%
5.73
Total Expenses
14.97
+15.74%
12.93
-24.81%
17.20
Operating Income
-14.66
-13.41%
-12.92
+23.59%
-16.91
Total Operating Income As Reported
-14.66
-13.41%
-12.92
+23.59%
-16.91
EBITDA
-14.40
-14.28%
-12.60
+24.04%
-16.59
Normalized EBITDA
-19.35
-91.85%
-10.09
+39.20%
-16.59
Reconciled Depreciation
0.26
-20.43%
0.32
-0.92%
0.33
EBIT
-14.66
-13.41%
-12.92
+23.59%
-16.91
Total Unusual Items
4.95
+296.82%
-2.52
—
Total Unusual Items Excluding Goodwill
4.95
+296.82%
-2.52
—
Net Income
-11.26
+21.82%
-14.41
+10.25%
-16.05
Pretax Income
-11.26
+21.82%
-14.41
+10.25%
-16.05
Other Income Expense
3.39
+328.79%
-1.48
-272.04%
0.86
Other Non Operating Income Expenses
-1.56
-250.87%
1.03
+19.72%
0.86
Gain On Sale Of Security
4.95
+296.82%
-2.52
—
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-11.26
+21.82%
-14.41
+10.25%
-16.05
Net Income From Continuing Operation Net Minority Interest
-11.26
+21.82%
-14.41
+10.25%
-16.05
Net Income From Continuing And Discontinued Operation
-11.26
+21.82%
-14.41
+10.25%
-16.05
Net Income Continuous Operations
-11.26
+21.82%
-14.41
+10.25%
-16.05
Normalized Income
-16.21
-36.34%
-11.89
+25.92%
-16.05
Net Income Common Stockholders
-11.26
+21.82%
-14.41
+10.25%
-16.05
Diluted EPS
-3.41
-111.52%
-1.61
+10.25%
-1.80
Basic EPS
-3.41
-111.52%
-1.61
+10.25%
-1.80
Basic Average Shares
3.30
-63.04%
8.94
+0.00%
8.94
Diluted Average Shares
3.30
-63.04%
8.94
+0.00%
8.94
Diluted NI Availto Com Stockholders
-11.26
+21.82%
-14.41
+10.25%
-16.05
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Assets
19.54
+254.58%
5.51
-35.07%
8.49
Current Assets
15.47
+417.74%
2.99
-41.11%
5.07
Cash Cash Equivalents And Short Term Investments
11.82
+647.94%
1.58
-51.70%
3.27
Cash And Cash Equivalents
11.82
+647.94%
1.58
-34.15%
2.40
Other Short Term Investments
—
0.00
-100.00%
0.87
Receivables
0.19
+2225.00%
0.01
-83.33%
0.05
Accounts Receivable
0.19
+2225.00%
0.01
-83.33%
0.05
Prepaid Assets
2.89
+1682.10%
0.16
-64.78%
0.46
Other Current Assets
0.57
-53.76%
1.24
-4.33%
1.29
Total Non Current Assets
4.07
+61.36%
2.52
-26.10%
3.41
Net PPE
2.35
+193.74%
0.80
-48.52%
1.55
Gross PPE
4.32
+67.60%
2.58
-15.19%
3.04
Accumulated Depreciation
-1.98
-11.01%
-1.78
-19.53%
-1.49
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
0.22
+10.50%
0.20
+12.36%
0.18
Other Properties
4.03
+74.69%
2.31
-17.34%
2.79
Leases
0.07
+0.00%
0.07
+0.00%
0.07
Other Non Current Assets
0.22
+0.00%
0.22
-38.12%
0.36
Total Liabilities Net Minority Interest
4.43
-89.58%
42.48
-31.96%
62.43
Current Liabilities
2.74
+35.95%
2.01
-13.93%
2.34
Payables And Accrued Expenses
1.90
+35.61%
1.40
-9.01%
1.54
Payables
1.80
+138.65%
0.75
+16.02%
0.65
Accounts Payable
1.80
+138.65%
0.75
+16.02%
0.65
Current Accrued Expenses
0.11
-83.56%
0.65
-27.18%
0.89
Pensionand Other Post Retirement Benefit Plans Current
0.31
+24.90%
0.25
+8.26%
0.23
Current Debt And Capital Lease Obligation
0.52
+44.88%
0.36
-36.33%
0.57
Current Capital Lease Obligation
0.52
+44.88%
0.36
-36.33%
0.57
Total Non Current Liabilities Net Minority Interest
1.69
-95.83%
40.47
-32.66%
60.09
Long Term Debt And Capital Lease Obligation
1.53
0.00
-100.00%
1.28
Long Term Debt
—
—
1.04
Long Term Capital Lease Obligation
1.53
0.00
-100.00%
0.24
Preferred Securities Outside Stock Equity
0.16
-99.60%
40.47
-31.20%
58.81
Stockholders Equity
15.11
+140.88%
-36.97
+31.47%
-53.94
Common Stock Equity
15.11
+140.88%
-36.97
+31.47%
-53.94
Capital Stock
0.79
+5153.33%
0.01
+150.00%
0.01
Common Stock
0.79
+5153.33%
0.01
+150.00%
0.01
Share Issued
9.02
+0.92%
8.94
+0.00%
8.94
Ordinary Shares Number
9.02
+0.92%
8.94
+0.00%
8.94
Additional Paid In Capital
96.52
+183.39%
34.06
+1167.15%
2.69
Retained Earnings
-82.31
-15.85%
-71.04
-25.44%
-56.64
Gains Losses Not Affecting Retained Earnings
0.11
0.00
—
Total Equity Gross Minority Interest
15.11
+140.88%
-36.97
+31.47%
-53.94
Total Capitalization
15.11
+140.88%
-36.97
+30.12%
-52.91
Working Capital
12.73
+1207.19%
0.97
-64.37%
2.73
Invested Capital
15.11
+140.88%
-36.97
+30.12%
-52.91
Total Debt
2.05
+467.59%
0.36
-80.41%
1.84
Capital Lease Obligations
2.05
+467.59%
0.36
-55.16%
0.81
Net Tangible Assets
15.11
+140.88%
-36.97
+31.47%
-53.94
Tangible Book Value
15.11
+140.88%
-36.97
+31.47%
-53.94
Financial Assets
1.50
+0.00%
1.50
+0.00%
1.50
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-13.72
-17.81%
-11.64
+22.66%
-15.05
Cash Flow From Continuing Operating Activities
-13.72
-17.81%
-11.64
+22.66%
-15.05
Net Income From Continuing Operations
-11.26
+21.82%
-14.41
+10.25%
-16.05
Depreciation Amortization Depletion
0.26
-20.43%
0.32
-0.92%
0.33
Depreciation
0.26
-20.43%
0.32
-0.92%
0.33
Depreciation And Amortization
0.26
-20.43%
0.32
-0.92%
0.33
Other Non Cash Items
0.61
+175.52%
-0.81
-235.73%
0.60
Stock Based Compensation
0.59
+1.38%
0.58
-25.42%
0.78
Operating Gains Losses
-4.95
-293.36%
2.56
+419.60%
-0.80
Gain Loss On Investment Securities
-4.95
-296.66%
2.52
+7091.67%
-0.04
Unrealized Gain Loss On Investment Securities
1.74
0.00
—
Gain Loss On Sale Of PPE
0.00
-100.00%
0.04
0.00
Change In Working Capital
-0.70
-712.28%
0.11
+18.75%
0.10
Change In Prepaid Assets
-0.14
-148.94%
0.28
+200.00%
-0.28
Change In Payables And Accrued Expense
0.04
+153.66%
-0.08
-108.26%
0.99
Change In Accrued Expense
-0.73
-291.40%
-0.19
-119.77%
0.94
Change In Payable
0.77
+642.31%
0.10
+100.00%
0.05
Change In Account Payable
0.77
+642.31%
0.10
+100.00%
0.05
Change In Other Current Assets
0.00
-100.00%
0.14
+592.86%
-0.03
Change In Other Current Liabilities
-0.60
-166.81%
-0.23
+61.37%
-0.58
Investing Cash Flow
15.54
+1581.82%
0.92
-93.74%
14.76
Cash Flow From Continuing Investing Activities
15.54
+1581.82%
0.92
-93.74%
14.76
Net PPE Purchase And Sale
-0.07
-220.37%
0.05
+112.24%
-0.44
Purchase Of PPE
-0.07
-58.54%
-0.04
+90.70%
-0.44
Sale Of PPE
0.00
-100.00%
0.10
0.00
Capital Expenditure
-0.07
-58.54%
-0.04
+90.70%
-0.44
Net Investment Purchase And Sale
0.00
-100.00%
0.87
-94.28%
15.20
Purchase Of Investment
0.00
+100.00%
-0.59
+87.86%
-4.89
Sale Of Investment
0.00
-100.00%
1.46
-92.71%
20.09
Net Business Purchase And Sale
15.61
0.00
—
Financing Cash Flow
7.82
-20.97%
9.90
+826.78%
1.07
Cash Flow From Continuing Financing Activities
7.82
-20.97%
9.90
+826.78%
1.07
Net Issuance Payments Of Debt
-0.06
0.00
-100.00%
1.04
Issuance Of Debt
—
0.00
-100.00%
1.04
Repayment Of Debt
-0.06
0.00
—
Long Term Debt Issuance
—
0.00
-100.00%
1.04
Long Term Debt Payments
-0.06
0.00
—
Net Long Term Debt Issuance
-0.06
0.00
-100.00%
1.04
Proceeds From Stock Option Exercised
0.01
-93.67%
0.08
+163.33%
0.03
Net Other Financing Charges
3.90
-2.79%
4.01
—
Changes In Cash
9.65
+1276.34%
-0.82
-206.22%
0.77
Effect Of Exchange Rate Changes
0.60
—
—
Beginning Cash Position
1.58
-34.15%
2.40
+47.39%
1.63
End Cash Position
11.82
+647.94%
1.58
-34.15%
2.40
Free Cash Flow
-13.78
-17.96%
-11.68
+24.60%
-15.49
Issuance Of Capital Stock
3.98
-31.45%
5.81
0.00
Net Preferred Stock Issuance
3.98
-31.45%
5.81
0.00
Preferred Stock Issuance
3.98
-31.45%
5.81
0.00
Sale Of Business
15.61
0.00
—
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category